Therapeutic strategies targeting cancer stem cells

References

• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105 - 11; http://dx.doi.org/10.1038/35102167; PMID: 11689955
   PubMed Web of Science ®Google Scholar
• Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007; 18:460 - 6; http://dx.doi.org/10.1016/j.copbio.2007.10.007; PMID: 18023337
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645 - 8; http://dx.doi.org/10.1038/367645a0; PMID: 7509044
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730 - 7; http://dx.doi.org/10.1038/nm0797-730; PMID: 9212098
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983 - 8; http://dx.doi.org/10.1073/pnas.0530291100; PMID: 12629218
   PubMed Web of Science ®Google Scholar
• Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65:5506 - 11; http://dx.doi.org/10.1158/0008-5472.CAN-05-0626; PMID: 15994920
   PubMed Web of Science ®Google Scholar
• Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15:504 - 14; http://dx.doi.org/10.1038/sj.cdd.4402283; PMID: 18049477
   PubMed Web of Science ®Google Scholar
• Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003; 100:15178 - 83; http://dx.doi.org/10.1073/pnas.2036535100; PMID: 14645703
   PubMed Web of Science ®Google Scholar
• Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821 - 8; PMID: 14522905
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64:7011 - 21; http://dx.doi.org/10.1158/0008-5472.CAN-04-1364; PMID: 15466194
   PubMed Web of Science ®Google Scholar
• O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106 - 10; http://dx.doi.org/10.1038/nature05372; PMID: 17122772
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445:111 - 5; http://dx.doi.org/10.1038/nature05384; PMID: 17122771
   PubMed Web of Science ®Google Scholar
• Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1:389 - 402; http://dx.doi.org/10.1016/j.stem.2007.08.001; PMID: 18371377
   PubMed Web of Science ®Google Scholar
• Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 2008; 105:13427 - 32; http://dx.doi.org/10.1073/pnas.0805706105; PMID: 18765800
   PubMed Web of Science ®Google Scholar
• Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65:10946 - 51; http://dx.doi.org/10.1158/0008-5472.CAN-05-2018; PMID: 16322242
   PubMed Web of Science ®Google Scholar
• Li CW, Heidt DG, Dalerba P, Burant CF, Zhang LJ, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-06-2030; PMID: 17283135
   PubMed Web of Science ®Google Scholar
• Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27:2875 - 83; PMID: 19816957
   PubMed Web of Science ®Google Scholar
• Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13:153 - 66; http://dx.doi.org/10.1016/j.ccr.2008.01.013; PMID: 18242515
   PubMed Web of Science ®Google Scholar
• Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007; 43:935 - 46; http://dx.doi.org/10.1016/j.ejca.2007.01.017; PMID: 17320377
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5:275 - 84; http://dx.doi.org/10.1038/nrc1590; PMID: 15803154
   PubMed Web of Science ®Google Scholar
• Rowan K. Are cancer stem cells real? After four decades, debate still simmers. J Natl Cancer Inst 2009; 101:546 - 7; http://dx.doi.org/10.1093/jnci/djp083; PMID: 19351923
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang Y. Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle 2008; 7:1360 - 70; http://dx.doi.org/10.4161/cc.7.10.5953; PMID: 18418062
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304 - 5; http://dx.doi.org/10.1136/bmj.38415.708634.F7; PMID: 15849206
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010; 123:271 - 9; http://dx.doi.org/10.1007/s10549-010-0763-9; PMID: 20135346
   PubMed Web of Science ®Google Scholar
• Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2009; 113:101 - 11; http://dx.doi.org/10.1007/s10549-008-9916-5; PMID: 18256928
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008; 3:18; http://dx.doi.org/10.1186/1750-2187-3-18; PMID: 19046439
   PubMedGoogle Scholar
• Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 2011; 15:166 - 78; http://dx.doi.org/10.1111/j.1582-4934.2009.00954.x; PMID: 19874425
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol 2010; 116:92 - 8; http://dx.doi.org/10.1016/j.ygyno.2009.09.024; PMID: 19822355
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 2010; 6:670 - 1; http://dx.doi.org/10.4161/auto.6.5.12434; PMID: 20559023
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27:3576 - 86; http://dx.doi.org/10.1038/sj.onc.1211024; PMID: 18212742
   PubMed Web of Science ®Google Scholar
• Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010; 16:2505 - 11; http://dx.doi.org/10.1158/1078-0432.CCR-09-2229; PMID: 20388847
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69:7507 - 11; http://dx.doi.org/10.1158/0008-5472.CAN-09-2994; PMID: 19752085
   PubMed Web of Science ®Google Scholar
• Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645 - 59; http://dx.doi.org/10.1016/j.cell.2009.06.034; PMID: 19682730
   PubMed Web of Science ®Google Scholar
• Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun 2010; 394:1098 - 104; http://dx.doi.org/10.1016/j.bbrc.2010.03.138; PMID: 20350531
   PubMed Web of Science ®Google Scholar
• Smith KM, Datti A, Fujitani M, Grinshtein N, Zhang L, Morozova O, et al. Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med 2010; 2:371 - 84; http://dx.doi.org/10.1002/emmm.201000093; PMID: 20721990
   PubMed Web of Science ®Google Scholar
• Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003; 149:39 - 52; http://dx.doi.org/10.1007/s10254-003-0013-1; PMID: 12811586
   PubMed Web of Science ®Google Scholar
• Yamashita T, Honda M, Nio K, Nakamoto Y, Yamashita T, Takamura H, et al. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res 2010; 70:4687 - 97; http://dx.doi.org/10.1158/0008-5472.CAN-09-4210; PMID: 20484035
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 2010; 16:2580 - 90; http://dx.doi.org/10.1158/1078-0432.CCR-09-2937; PMID: 20388854
   PubMed Web of Science ®Google Scholar
• Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK. The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 2010; 18:5 - 14; PMID: 20718984
   PubMedGoogle Scholar
• Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol 2010; 37:551 - 61; PMID: 20664924
   PubMed Web of Science ®Google Scholar
• Hsu HS, Lin JH, Huang WC, Hsu TW, Su K, Chiou SH, et al. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer 2011; 117:1516 - 28; http://dx.doi.org/10.1002/cncr.25599; PMID: 21425153
   PubMed Web of Science ®Google Scholar
• Fong D, Yeh A, Naftalovich R, Choi TH, Chan MM. Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett 2010; 293:65 - 72; http://dx.doi.org/10.1016/j.canlet.2009.12.018; PMID: 20089354
   PubMed Web of Science ®Google Scholar
• Kim JB, Ko E, Han W, Shin I, Park SY, Noh DY. Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. Planta Med 2008; 74:1693 - 700; http://dx.doi.org/10.1055/s-0028-1088313; PMID: 18951337
   PubMed Web of Science ®Google Scholar
• Luk SU, Yap WN, Chiu YT, Lee DT, Ma S, Lee TK, et al. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int J Cancer 2011; 128:2182 - 91; http://dx.doi.org/10.1002/ijc.25546; PMID: 20617516
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu WL, Guo J, Du J, Li T, Wu JW, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 2008; 129:18 - 25; http://dx.doi.org/10.1016/j.jconrel.2008.03.022; PMID: 18466993
   PubMed Web of Science ®Google Scholar
• Imai Y, Tsukahara S, Asada S, Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 2004; 64:4346 - 52; http://dx.doi.org/10.1158/0008-5472.CAN-04-0078; PMID: 15205350
   PubMed Web of Science ®Google Scholar
• Ries SJ, Brandts CH. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov Today 2004; 9:759 - 68; http://dx.doi.org/10.1016/S1359-6446(04)03221-0; PMID: 15450242
   PubMed Web of Science ®Google Scholar
• Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 2008; 68:5533 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-07-5288; PMID: 18632604
   PubMed Web of Science ®Google Scholar
• Zhang X, Komaki R, Wang L, Fang B, Chang JY. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin Cancer Res 2008; 14:2813 - 23; http://dx.doi.org/10.1158/1078-0432.CCR-07-1528; PMID: 18451249
   PubMed Web of Science ®Google Scholar
• He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5:522 - 31; http://dx.doi.org/10.1038/nrg1379; PMID: 15211354
   PubMed Web of Science ®Google Scholar
• Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, et al. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 2009; 26:27 - 34; PMID: 19242066
   PubMed Web of Science ®Google Scholar
• Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res 2009; 15:1177 - 83; http://dx.doi.org/10.1158/1078-0432.CCR-08-1355; PMID: 19228723
   PubMed Web of Science ®Google Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65:6029 - 33; http://dx.doi.org/10.1158/0008-5472.CAN-05-0137; PMID: 16024602
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14:2348 - 60; http://dx.doi.org/10.1261/rna.1034808; PMID: 18812439
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783; PMID: 16103053
   PubMed Web of Science ®Google Scholar
• Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17:1298 - 307; http://dx.doi.org/10.1016/j.cub.2007.06.068; PMID: 17656095
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447:1130 - 4; http://dx.doi.org/10.1038/nature05939; PMID: 17554337
   PubMed Web of Science ®Google Scholar
• Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8:266; http://dx.doi.org/10.1186/1471-2407-8-266; PMID: 18803879
   PubMed Web of Science ®Google Scholar
• Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4:e6816; http://dx.doi.org/10.1371/journal.pone.0006816; PMID: 19714243
   PubMed Web of Science ®Google Scholar
• Yang YP, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL, et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012; 33:1462 - 76; http://dx.doi.org/10.1016/j.biomaterials.2011.10.071; PMID: 22098779
   PubMed Web of Science ®Google Scholar
• Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008; 7:2725 - 35; http://dx.doi.org/10.1158/1535-7163.MCT-08-0573; PMID: 18790753
   PubMed Web of Science ®Google Scholar
• Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009; 8:310 - 4; http://dx.doi.org/10.1158/1535-7163.MCT-08-0924; PMID: 19174553
   PubMed Web of Science ®Google Scholar
• Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009; 137:1102 - 13; http://dx.doi.org/10.1053/j.gastro.2009.05.053; PMID: 19501590
   PubMed Web of Science ®Google Scholar
• Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007; 25:2524 - 33; http://dx.doi.org/10.1634/stemcells.2007-0166; PMID: 17628016
   PubMed Web of Science ®Google Scholar
• Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010; 70:709 - 18; http://dx.doi.org/10.1158/0008-5472.CAN-09-1681; PMID: 20068161
   PubMed Web of Science ®Google Scholar
• Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5:168 - 77; http://dx.doi.org/10.1016/j.stem.2009.05.019; PMID: 19664991
   PubMed Web of Science ®Google Scholar
• Zhang Y, Piao B, Zhang Y, Hua B, Hou W, Xu W, et al. Oxymatrine diminishes the side population and inhibits the expression of β-catenin in MCF-7 breast cancer cells. Med Oncol 2011; 28:Suppl 1 S99 - 107; http://dx.doi.org/10.1007/s12032-010-9721-y; PMID: 21069479
   PubMed Web of Science ®Google Scholar
• Jiang Y, Boije M, Westermark B, Uhrbom L. PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Neoplasia 2011; 13:492 - 503; PMID: 21677873
   PubMed Web of Science ®Google Scholar
• Dong Y, Han Q, Zou Y, Deng Z, Lu X, Wang X, et al. Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. Mol Cell Biochem 2012; 370:89 - 102; http://dx.doi.org/10.1007/s11010-012-1401-0; PMID: 22829019
   PubMed Web of Science ®Google Scholar
• Garth S. NIH funds first cancer stem cell clinical trial at University of Colorado Cancer Center. Colorado Cancer Blogs(News and Views from the University of Colorado Cancer). September 19, 2011 .
   Google Scholar
• Bonavida B, Ng CP, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol 1999; 15:793 - 802; PMID: 10493964
   PubMed Web of Science ®Google Scholar
• Zobalova R, McDermott L, Stantic M, Prokopova K, Dong LF, Neuzil J. CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochem Biophys Res Commun 2008; 373:567 - 71; http://dx.doi.org/10.1016/j.bbrc.2008.06.073; PMID: 18590703
   PubMed Web of Science ®Google Scholar
• Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, Herold-Mende C, et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol 2009; 117:445 - 56; http://dx.doi.org/10.1007/s00401-009-0494-3; PMID: 19214542
   PubMed Web of Science ®Google Scholar
• Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS. Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 2007; 6:1490 - 5; http://dx.doi.org/10.4161/cbt.6.9.4905; PMID: 17881904
   PubMed Web of Science ®Google Scholar
• Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008; 15:730 - 8; http://dx.doi.org/10.1038/gt.2008.39; PMID: 18401438
   PubMed Web of Science ®Google Scholar
• Choi SA, Hwang SK, Wang KC, Cho BK, Phi JH, Lee JY, et al. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro Oncol 2011; 13:61 - 9; http://dx.doi.org/10.1093/neuonc/noq147; PMID: 21062796
   PubMed Web of Science ®Google Scholar
• Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, et al. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008; 12:6B 2628 - 43; http://dx.doi.org/10.1111/j.1582-4934.2008.00317.x; PMID: 18373740
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Sage EK, Davies D, Janes SM. TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br J Cancer 2010; 103:1692 - 7; http://dx.doi.org/10.1038/sj.bjc.6605952; PMID: 21063402
   PubMed Web of Science ®Google Scholar
• Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6:34 - 55; http://dx.doi.org/10.1634/theoncologist.6-1-34; PMID: 11161227
   PubMed Web of Science ®Google Scholar
• Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 2005; 4:3 - 8; http://dx.doi.org/10.2174/1568010053622830; PMID: 15720228
   PubMedGoogle Scholar
• Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 2008; 68:5658 - 68; http://dx.doi.org/10.1158/0008-5472.CAN-07-6341; PMID: 18632618
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Seino K, Hosonuma S, Ohara T, Itamochi H, Isonishi S, et al. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. Gynecol Oncol 2011; 121:390 - 4; http://dx.doi.org/10.1016/j.ygyno.2010.12.366; PMID: 21272926
   PubMed Web of Science ®Google Scholar
• Yuki K, Natsume A, Yokoyama H, Kondo Y, Ohno M, Kato T, et al. Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett 2009; 284:71 - 9; http://dx.doi.org/10.1016/j.canlet.2009.04.020; PMID: 19457609
   PubMed Web of Science ®Google Scholar
• Holt SE, Shay JW, Wright WE. Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol 1996; 14:836 - 9; http://dx.doi.org/10.1038/nbt0796-836; PMID: 9631006
   PubMed Web of Science ®Google Scholar
• Röth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)--telomerase-based cancer therapy. Recent Results Cancer Res 2010; 184:221 - 34; http://dx.doi.org/10.1007/978-3-642-01222-8_16; PMID: 20072842
   PubMedGoogle Scholar
• Brennan SK, Wang Q, Tressler R, Harley C, Go N, Bassett E, et al. Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 2010; 5; http://dx.doi.org/10.1371/journal.pone.0012487; PMID: 20824134
   PubMed Web of Science ®Google Scholar
• Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010; 70:9494 - 504; http://dx.doi.org/10.1158/0008-5472.CAN-10-0233; PMID: 21062983
   PubMed Web of Science ®Google Scholar
• Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010; 16:154 - 63; http://dx.doi.org/10.1158/1078-0432.CCR-09-2850; PMID: 20048334
   PubMed Web of Science ®Google Scholar
• Siddikuzzaman GC, Guruvayoorappan C, Berlin Grace VM. All trans retinoic acid and cancer. Immunopharmacol Immunotoxicol 2011; 33:241 - 9; http://dx.doi.org/10.3109/08923973.2010.521507; PMID: 20929432
   PubMed Web of Science ®Google Scholar
• Karsy M, Albert L, Tobias ME, Murali R, Jhanwar-Uniyal M. All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner. Anticancer Res 2010; 30:4915 - 20; PMID: 21187470
   PubMed Web of Science ®Google Scholar
• Papi A, Guarnieri T, Storci G, Santini D, Ceccarelli C, Taffurelli M, et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ 2012; 19:1208 - 19; http://dx.doi.org/10.1038/cdd.2011.207; PMID: 22261616
   PubMed Web of Science ®Google Scholar
• Lim YC, Kang HJ, Kim YS, Choi EC. All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt/β-catenin pathway. Eur J Cancer 2012; 48:3310 - 8; http://dx.doi.org/10.1016/j.ejca.2012.04.013; PMID: 22640830
   PubMed Web of Science ®Google Scholar
• Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008; 26:3008 - 17; http://dx.doi.org/10.1634/stemcells.2008-0601; PMID: 18802032
   PubMed Web of Science ®Google Scholar
• Wang CH, Chiou SH, Chou CP, Chen YC, Huang YJ, Peng CA. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 2011; 7:69 - 79; http://dx.doi.org/10.1016/j.nano.2010.06.010; PMID: 20620237
   PubMed Web of Science ®Google Scholar
• Salnikov AV, Groth A, Apel A, Kallifatidis G, Beckermann BM, Khamidjanov A, et al. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J Cell Mol Med 2009; 13:9B 4023 - 33; http://dx.doi.org/10.1111/j.1582-4934.2009.00723.x; PMID: 20196789
   PubMedGoogle Scholar
• Qiu M, Peng Q, Jiang I, Carroll C, Han G, Rymer I, et al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett 2013; 328:261 - 70; http://dx.doi.org/10.1016/j.canlet.2012.09.023; PMID: 23041621
   PubMed Web of Science ®Google Scholar
• Petrie K, Zelent A, Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009; 16:84 - 91; http://dx.doi.org/10.1097/MOH.0b013e3283257aee; PMID: 19468269
   PubMed Web of Science ®Google Scholar